The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.121.5.491

Two separate double-blind studies comparing the incidence of withdrawal emesis after the abrupt cessation of medication, one using an inert placebo and the second using phenobarbital as control agents, revealed highly significant differences between the antipsychotic compounds (phenothiazine and butyrophenone derivatives) and the control groups (placebo and phenobarbital). Thorough medical evaluation, including gastric analyses, ruled out gastritis as an etiology of the gastrointestinal withdrawal symptom. It would thus appear that abrupt termination of these antipsychotic medications in chronic schizophrenics does produce gastrointestinal withdrawal symptoms of CNS origin in a significant number of treated subjects.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.